SCHEMBL4840276

SCHEMBL4840276

CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(CCl)c(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 20/20 0.70
PPARD Q03181 3/20 0.70
LIFR P42702 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838421 0.90 NR1H4 (0.76) NR1H4PPARDLIFR
SCHEMBL20094448 0.87 NR1H4 (0.73) NR1H4PPARDLIFR
SCHEMBL4835579 0.86 NR1H4 (0.71) NR1H4PPARDLIFR
SCHEMBL4838231 0.84 NR1H4 (0.85) NR1H4PPARDLIFR
SCHEMBL4598944 0.83 NR1H4 (0.87) NR1H4PPARDLIFR
SCHEMBL4797323 0.83 NR1H4 (0.78) NR1H4LIFR
SCHEMBL3994761 0.83 NR1H4 (0.69) NR1H4PPARDLIFR
SCHEMBL19499079 0.83 NR1H4 (0.82) NR1H4PPARDLIFR
SCHEMBL4435961 0.83 NR1H4 (0.86) NR1H4PPARDLIFR
SCHEMBL24425708 0.83 NR1H4 (1.00) NR1H4PPARDLIFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319109-B2 Farnesoid X receptor agonists SMITH KLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-20060258725-A1 Farnesoid x receptor agonists SMITHKLINE BEECHAM CORPORATION 2006-11-16 US disclosed
EP-1562915-A1 FARNESOID X RECEPTOR AGONISTS SmithKline Beecham Corporation (US) 2005-08-17 EP disclosed
WO-2004048349-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258725-A1 Farnesoid x receptor agonists NR1H4, GPBAR1, NR1H2 NR1H4 1/4885PPARD 178/4885LIFR 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.